Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families Authors: Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield Published: 2026 ABSTRACT ABSTRACTRecent publications reporting increased cutaneous T‐cell lymphoma (CTCL) risk with dupilumab in atopic dermatitis (AD) have sparked debate, amplified by media coverage linking dupilumab to lymphoma. These concerns have reached pediatric populations, where we observe increasing parental hesitancy about initiating dupilumab for their children. This hesitancy is particularly acute given that dupilumab was only approved for infants aged 6 months and older in 2022—the first cohort now approaching 3–4 years of exposure. Parents understandably question the long‐term effects of decades of IL‐4/IL‐13 blockade initiated during critical immune development periods. The diagnostic overlap between AD and mycosis fungoides (the most common CTCL) complicates assessment. We examine evidence regarding dupilumab safety and CTCL risk specifically in pediatric patients, incorporating recently presented long‐term open‐label extension data, and provide recommendations for monitoring, distinguishing AD from CTCL, and counseling families navigating this complex topic. Introduction Atopic dermatitis is a chronic inflammatory skin disease affecting up to 20% of children worldwide, with a significant impact on patients' and caregivers' quality of life [1]. Dupilumab, a fully human monoclonal antibody that inhibits IL‐4 and IL‐13 signaling through blockade of IL‐4Rα, is the first biologic therapy approved for moderate‐to‐severe AD in patients aged 6 months and older [1]. Phase 3 clinical trials have demonstrated significant improvements in disease severity, pruritus, and quality of life in pediatric populations, with an acceptable safety profile consistent with observations in adults [1, 2]. The relationship between AD and CTCL has long been recognized as complex. Mycosis fungoides (MF), the most common CTCL subtype, can clinically mimic AD, and Sézary syndrome can present similarly to atopic erythroderma [3, 4]. This diagnostic overlap, combined with reports of CTCL diagnoses following dupilumab initiation in adult patients, has prompted investigation into whether dupilumab poses an oncogenic risk or whether it unmasks pre‐existing malignancy [5, 6]. In this narrative review, we aim to examine the evidence regarding dupilumab safety and CTCL risk specifically in pediatric patients, incorporating recently presented long‐term open‐label extension data and current clinical recommendations to properly inform clinicians how to counsel pediatric patients and their families, including sample language for these discussions. We conducted a comprehensive literature search of PubMed, Embase, and http://clinicaltrials.gov through April 2025 using the terms “dupilumab,” “atopic dermatitis,” “cutaneous T‐cell lymphoma,” “mycosis fungoides,” and “pediatric,” supplemented by review of relevant conference abstracts, FDA drug labels, and pharmacovigilance databases. Epidemiology of CTCL in Pediatric Populations CTCL is predominantly a disease of older adults, with incidence increasing dramatically with age [7]. The overall incidence of CTCL is estimated at 8.8 cases per million persons, with MF accounting for approximately 5.2 cases per million [8]. Pediatric CTCL is exceedingly rare, representing less than 1.25% of all primary cutaneous lymphoma cases [9]. When CTCL does occur in children, it demonstrates distinct characteristics compared to adult disease. The hypopigmented variant of MF is very common in pediatric populations, and Sézary syndrome is extremely rare in children [1, 10]. The overwhelming majority of pediatric patients present with early‐stage disease, and progression to advanced stages is uncommon [10]. Importantly, the diagnosis of CTCL in children is frequently delayed due to clinical mimicry of common inflammatory dermatoses, including AD [1, 11]. However, CTCL in children has an excellent prognosis and is readily treatable; the majority of children respond well to skin‐directed therapies such as topical corticosteroids and phototherapy, with 5‐year and 10‐year disease‐specific survival rates of 100% in recent series [10, 11]. Atopic Dermatitis and Lymphoma Risk Population‐based studies have demonstrated an association between AD and increased lymphoma risk, particularly in patients with severe disease. A meta‐analysis found that AD was significantly associated with elevated lymphoma risk (OR 2.56, 95% CI: 1.75–3.74), with T‐cell lymphoma showing the highest risk (OR 4.25, 95% CI: 1.94–9.33) [12]. In a large UK and Danish cohort study, severe AD was associated with a 2‐fold increased risk of non‐Hodgkin lymphoma (NHL adjusted HR 2.08, 99% CI: 1.42–3.04). Severe AD is associated with a 2–3‐fold increased risk of lymphoma, including CTCL, even after adjusting for disease severity and drug exposure [13, 14]. In pediatric populations specifically, a large UK cohort study found that, excluding CTCL, severe AD in children was associated with increased lymphoma risk (HR 3.18, 95% CI: 1.41–7.16), though overall malignancy risk did not differ significantly between children with and without AD [14]. Several mechanisms have been proposed for the association between AD and lymphoma risk. Chronic immune stimulation and persistent T‐cell activation in severe AD may promote clonal T‐cell expansion. Additionally, shared cytokine signaling pathways—particularly IL‐13 and IL‐4—play roles in both AD pathogenesis and CTCL tumor biology. The diagnostic overlap between severe AD and early‐stage CTCL also raises the possibility that some of the observed associations reflect misclassification rather than a true causal relationship, as investigators have cautioned that misdiagnosis between severe AD and early‐stage CTCL could not be ruled out even after long follow‐up periods [13]. Dupilumab Clinical Trial Data in Pediatric Populations The dupilumab clinical development program includes multiple phase 3 randomized trials and extension studies across pediatric age groups. In children aged 6 months to younger than 6 years with moderate‐to‐severe atopic dermatitis (AD), dupilumab demonstrated significant clinical benefit with an overall safety profile comparable to placebo, including lower serious treatment‐emergent adverse events (TEAEs) in the dupilumab arm [1]. The LIBERTY AD PRESCHOOL phase 3 trial enrolled 162 children aged 6 months to younger than 6 years (the youngest patient in the dupilumab group was aged 10 months); patients received dupilumab or placebo every 4 weeks for 16 weeks, with eligible patients subsequently enrolling in the LIBERTY AD PED open‐label extension (OLE) study [1]. In the OLE, 180 patients from this age group were followed for up to 2 years (104 weeks), with 106 completing the week 104 visit; the safety profile remained consistent with the parent study, with no new safety signals detected [1, 15]. Longer‐term open‐label extension data in children aged ≥ 6 to 12 years similarly support a stable safety profile over extended follow‐up [5]. Importantly, across the dupilumab pediatric AD clinical program (6 months–17 years), there have been no reported TEAEs of cutaneous T‐cell lymphoma (CTCL), including mycosis fungoides (MF), in controlled trials or available extension studies [2]. These pediatric findings are reassuring given the rarity of CTCL in childhood and the clinical overlap between severe or erythrodermic AD and early CTCL. CTCL Reports in Adult Dupilumab‐Treated Patients In adults, sporadic CTCL diagnoses have been reported during dupilumab therapy, prompting concern for either de novo oncogenesis or diagnostic unmasking of pre‐existing CTCL. In the adult AD open‐label extension program with follow‐up to 260 weeks (5 years), mycosis fungoides was reported in three (0.1%) dupilumab‐treated patients; investigators assessed these events as unrelated to the study drug [1]. A recent comprehensive review reported that 124 patients developed lymphoproliferative disorders after dupilumab, with a median time to diagnosis of 5 months after dupilumab initiation; 39% of cases presented with advanced‐stage disease [2]. A contemporaneous clinical review emphasizes that the observed association is most consistent with diagnostic unmasking or accelerated recognition of underlying CTCL in a subset of patients with refractory dermatitis, rather than a causal carcinogenic effect [6]. Proposed Mechanisms: Unmasking Versus Oncogenesis Current evidence does not support a direct oncogenic effect of dupilumab. The proposed mechanism for CTCL emergence during dupilumab therapy involves the unmasking of pre‐existing malignant T‐cell clones rather than de novo transformation. IL‐4Rα blockade leads to increased IL‐13 availability in the local microenvironment, which may stimulate CTCL progression through IL‐13 receptor alpha 2 (IL‐13Rα2) signaling on tumor cells [2, 3, 6]. This hypothesis is supported by observations that: (1) Many patients diagnosed with CTCL after dupilumab had histopathologic evidence of MF on pre‐treatment biopsies when retrospectively reviewed; (2) The median time to diagnosis (5 months) is shorter than would be expected for de novo malignancy development; (3) Patients often present with advanced‐stage disease, suggesting pre‐existing occult malignancy [2, 4]. IL‐13 and its receptors IL‐13Rα1 and IL‐13Rα2 are highly expressed in the clinically involved skin of CTCL patients, and malignant lymphoma cells produce IL‐13 and express both receptors [3]. IL‐13 induces CTCL cell growth in vitro through IL‐13Rα1 signaling, and antibody‐mediated neutralization of IL‐13 or soluble IL‐13Rα2 molecules can lead to inhibition of tumor‐cell proliferation, implicating IL‐13 as an autocrine factor in CTCL [3]. A comprehensive review concluded that “no evidence is available to support a direct oncogenic risk of transforming AD into lymphoma by the treatment, and current literature suggests the role of IL‐4Rα/IL‐13R inhibition in unmasking pre‐existing malignant T cell clones through increased IL‐13 availability” [6]. Regulatory Assessment Regulatory bodies have reviewed post‐marketing reports of CTCL in dupilumab‐treated patients. The available evidence does not support a causal association between dupilumab and CTCL, with the observed association likely representing diagnostic unmasking in a population (severe AD) already at elevated baseline risk for CTCL, rather than a drug‐induced oncogenic effect [6]. Distinguishing AD from CTCL: Pediatric‐Specific Considerations Given the extreme rarity of pediatric CTCL, routine pre‐treatment biopsy is not indicated for typical pediatric AD. However, persistent treatment‐refractory dermatitis, atypical lesions, systemic symptoms, or unexplained lymphadenopathy should prompt biopsy and multidisciplinary evaluation [10, 16]. Key distinguishing features are summarized in Table 1. TABLE 1Features distinguishing CTCL from AD.FeatureAtopic dermatitisCTCL (mycosis fungoides)Age of onsetTypically, infancy/early childhoodPredominantly older adults; rare in childrenDistributionFlexural (antecubital/popliteal fossae), face in infants; age‐dependentBathing‐trunk distribution; non‐sun‐exposed areas (buttocks, thighs, trunk)MorphologyErythematous, excoriated, lichenified plaques; oozing in acute phase Well‐demarcated patches/plaques with fine wrinkling; poikiloderma; Hypopigmented patches (common pediatric variant) Folliculotropic MF with keratosis pilaris‐like lesions PruritusProminent, often severeVariable; may be less prominent in early‐stage MFResponse to conventional AD therapyTypically responds to topical corticosteroids, emollients, topical non steroids, systemic IL4R, IL13 or JAK inhibitorsPoor or incomplete response to conventional AD therapy; may initially improve then plateau or worsenAtopic historyPersonal/family history of atopy (asthma, allergic rhinitis, food allergy)Typically absent; adult‐onset “eczema” without atopic history is a red flagSerum IgEOften elevatedTypically, normal or lowHistopathologySpongiosis, perivascular lymphocytic infiltrate; no epidermotropism of atypical lymphocytesEpidermotropism of atypical lymphocytes with cerebriform nuclei; Pautrier microabscesses; band‐like lymphocytic infiltrateImmunophenotypeMixed CD4+/CD8+ T‐cell infiltrate; preserved pan‐T‐cell markersCD3+, CD4+, CD8−; loss of CD7 and/or CD26; aberrant T‐cell phenotypeT‐cell clonality (TCR gene rearrangement)PolyclonalMonoclonal TCR rearrangement (though may be absent in early disease)Systemic symptomsReactive lymphadenopathy and erythroderma may occur in severe AD but and improve with AD treatmentPersistent or progressive lymphadenopathy disproportionate to skin disease; erythroderma unresponsive to AD therapy; blood involvement with circulating Sézary cells (Sézary syndrome) in advanced disease Features distinguishing CTCL from AD. Well‐demarcated patches/plaques with fine wrinkling; poikiloderma; Hypopigmented patches (common pediatric variant) Folliculotropic MF with keratosis pilaris‐like lesions It is worth noting that lack of response to conventional AD therapy is itself a criterion for dupilumab initiation; therefore, treatment refractoriness should be interpreted in context—specifically, clinicians should consider biopsy when the clinical presentation is atypical or when there is a qualitative change in disease morphology or distribution after initiating dupilumab, rather than solely on the basis of prior treatment failure. In pediatric patients specifically, the hypopigmented variant of MF is overrepresented and may mimic vitiligo or pityriasis alba, while folliculotropic MF can present with follicular accentuation or keratosis pilaris‐like lesions that may be mistaken for common pediatric dermatoses [10]. A high index of suspicion is necessary for accurate diagnosis, particularly in children with refractory eczematous dermatitis. Table 2 describes clinical approaches based on available trial data, published literature, and recent expert consensus that can help mitigate diagnostic delay and inappropriate continuation of dupilumab in patients with unrecognized CTCL. While these recommendations were developed primarily for adult populations, the principles of careful clinical assessment, appropriate use of biopsy when clinical features are atypical, and reassessment during treatment apply to pediatric patients as well. The key difference in pediatric practice is maintaining a lower threshold for considering alternative diagnoses given the extreme rarity of CTCL in this age group, while recognizing that diagnostic delay is common when CTCL does occur in children [2, 4, 6]. TABLE 2Clinical recommendations to mitigate diagnostic delay and inappropriate continuation of dupilumab in patients with unrecognized CTCL.Clinical scenario/triggerRecommended evaluation and managementKey tests/thresholdsBefore initiating dupilumab in adults with newly diagnosed or atypical dermatitisConsider CTCL upfront when clinical features are not typical for AD; lower threshold to biopsy before starting biologic therapy.Higher concern if onset > 40 years, no personal atopic history, atypical distribution (nonflexural, follicular lesions, alopecia, erythroderma, palmoplantar keratoderma), or lymphadenopathy.When clinical suspicion is elevated (pre‐treatment or on treatment)Obtain skin biopsy for histopathology (preferably dermatopathology review) and consider TCR clonality; avoid initiating or continuing dupilumab until CTCL is reasonably excluded.Biopsy from the most representative/active sites; add TCR gene rearrangement when clinicopathologic discordance exists.During dupilumab therapyReassess diagnosis if atypical worsening, morphologic change, or lack of meaningful improvement; repeat biopsy and escalate systemic evaluation when disease is extensive.Add peripheral blood flow cytometry and skin/blood clonality when erythroderma or widespread involvement (> 50% BSA) is present.If CTCL is confirmed during dupilumab treatmentDiscontinue dupilumab and initiate stage‐appropriate CTCL management promptly.In nonaggressive presentations, a short 1–3‐month symptom‐directed observation period after discontinuation may be reasonable with close monitoring.If biopsy is inconclusive but suspicion persistsMaintain close follow‐up and repeat biopsy and/or blood studies rather than escalating dupilumab; consider alternative systemic dermatitis therapies based on clinical context.Re‐evaluate at ~3 months (or sooner with progression); repeat sampling from evolving lesions and reassess blood involvement if systemic signs emerge.Abbreviations: AD, atopic dermatitis; BSA, body surface area; CTCL, cutaneous T‐cell lymphoma; TCR, T‐cell receptor. Clinical recommendations to mitigate diagnostic delay and inappropriate continuation of dupilumab in patients with unrecognized CTCL. Abbreviations: AD, atopic dermatitis; BSA, body surface area; CTCL, cutaneous T‐cell lymphoma; TCR, T‐cell receptor. Comparative Risks with Other Systemic Therapies for Younger Patients Prior to the availability of dupilumab, systemic treatment options for severe atopic dermatitis were limited to conventional immunosuppressants such as methotrexate (MTX) and cyclosporine, which are associated with well‐documented malignancy risks. MTX has been associated with increased risks of basal cell carcinoma (OR 1.29, 95% CI 1.20–1.38), squamous cell carcinoma (OR 1.61, 95% CI 1.37–1.89), and melanoma (OR 1.35, 95% CI 1.13–1.61), with evidence of dose–response relationships for nonmelanoma skin cancers [17]. Additionally, methotrexate carries a recognized risk of methotrexate‐associated lymphoproliferative disorder (MTX‐LPD), an iatrogenic lymphoproliferative condition most commonly of B‐cell lineage that can develop during chronic MTX therapy; while predominantly described in rheumatoid arthritis populations, MTX‐LPD is relevant to any discussion of lymphoma risk with systemic AD therapies, as it may regress upon MTX withdrawal but can also require chemotherapy in a subset of patients [18]. Cyclosporine carries established risks of cutaneous and lymphoproliferative malignancies, particularly with prolonged use; in renal transplant recipients, dose‐dependent increases in cancer risk begin at 2 years and continue through 7 years of treatment, with malignancy representing the most common cause of death in long‐term studies [19, 20]. These conventional immunosuppressants also require intensive monitoring for nephrotoxicity, hepatotoxicity, bone marrow suppression, and other serious adverse effects [19, 20, 21]. Janus kinase (JAK) inhibitors, including upadacitinib (approved for AD in patients ≥ 12 years) and abrocitinib, represent another class of systemic therapy now available for adolescents with moderate‐to‐severe AD [22, 23]. While JAK inhibitors have demonstrated high efficacy, they carry FDA boxed warnings for serious infections, malignancies (including lymphoma), major adverse cardiovascular events, and thrombosis, based primarily on data from the ORAL Surveillance trial in older rheumatoid arthritis patients [22, 24]. The relevance of these warnings to younger AD populations remains uncertain. Still, they underscore the importance of contextualizing the theoretical CTCL concern with dupilumab against the established risk profiles of alternative systemic agents [21, 22]. The theoretical CTCL concern—unsupported by pediatric data—should be weighed against demonstrated benefits. Counseling Families: A Practical Approach Effective counseling requires acknowledging parental concerns while providing accurate, accessible information. Key counseling points are summarized in Table 3. TABLE 3Key counseling points and sample language for families (dupilumab and CTCL).Counseling domainKey pointsSample languageValidate the concernParents may encounter alarming online content; dismissing anxiety undermines trust; questions about long‐term safety in infants are legitimate given the medication's recent approval in this age group“I understand you've heard concerns about dupilumab and a rare skin cancer. These are reasonable questions, and I want to make sure you have accurate information.”Provide context: CTCL rarity in childrenCTCL almost never occurs in children (1.25% of all cutaneous lymphomas); it is predominantly a disease of older adults; when it does occur in children, it has an excellent prognosis and is readily treatable“This type of cancer is extremely rare in children—it primarily affects older adults. When it does occur in children, it responds very well to treatment.”Provide context: pediatric trial safety dataNo cases of CTCL have emerged in any pediatric dupilumab trial (ages 6 months–17 years), including open‐label extension studies with up to 2 years of follow‐up; the youngest patient in the dupilumab group was aged 10 months“In all clinical trials of dupilumab in children, including studies starting at 6 months of age with up to 2 years of follow‐up, there have been zero cases of this cancer.”Provide context: unmasking, not causationThe adult association likely reflects revealing hidden disease rather than causing cancer; many adult cases had pre‐existing CTCL on retrospective biopsy review; regulatory agencies found no causal link“The cases reported in adults appear to involve cancer that was already present but looked like eczema. Regulatory agencies reviewed this carefully and found no evidence that dupilumab causes cancer.”Frame the risk–benefit discussionModerate‐to‐severe AD significantly impacts quality of life, sleep, growth, and mental health; before dupilumab, systemic options for young children were limited to broad immunosuppressants with substantial toxicity; JAK inhibitors carry FDA boxed warnings for malignancies including lymphoma; the theoretical CTCL concern is unsupported by pediatric data“Uncontrolled eczema can significantly affect your child's sleep, development, and quality of life. Dupilumab is the safest systemic option we have for young children—the alternatives carry more established risks.”Emphasize safety netsRegular follow‐up allows ongoing clinical assessment; biopsies can be performed if any concerns arise; dupilumab's effects are reversible upon discontinuation“We will monitor your child closely at every visit. If any concerns ever arise, we can perform a skin biopsy or stop the medication—its effects are reversible.”Shared decision‐makingAcknowledge that the decision is ultimately the family's; offer to revisit the discussion; provide written materials if helpful“This is your decision, and I support whatever you choose. We can revisit this conversation anytime as new information becomes available.” Key counseling points and sample language for families (dupilumab and CTCL). Conclusions For pediatric patients, the evidence is reassuring: no CTCL cases in any pediatric dupilumab trial, including open‐label extension data with up to 2 years of follow‐up. The extreme rarity of childhood CTCL, absence of reported cases, and regulatory conclusions support continued confidence in dupilumab's pediatric safety profile. Effective counseling requires acknowledging parental concerns—including legitimate questions about long‐term safety in children started on biologics since infancy—providing accurate context‐appropriate information and engaging in shared decision‐making. Clinicians should feel confident reassuring families while maintaining appropriate diagnostic vigilance. Withholding effective therapy based on theoretical concerns unsupported by pediatric data would not serve patients' best interests, particularly given the substantial burden of uncontrolled AD on children and their families. Funding The authors have nothing to report. Conflicts of Interest LFE has served as a consultant, advisor or investigator for AbbVie, Abeona, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol‐Myers Squibb, Castle Biosciences, Chiesi, Corevitas, Dermavant, Enveda, Formation Bio, Forte, Galderma, Incyte, Janssen, Kenvue, Kymera, Krystal, LEO, Lilly, Nektar, Novartis, OrthoDerm, Pfizer, Regeneron, Sanofi Genzyme, Takeda, Target RWE, T‐Rex, UCB and Verrica. [Correction added on 21 July 2026, after first online publication: The Conflicts of Interest statement has been added.]